Sancure Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Sancure Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, gr…

2012-12-05 Bhubaneswar, Orissa Active Unlisted Active Compliant
Share
SP Sancure Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Sancure Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
72/100
Trust Score
Moderate

Sancure Pharmaceuticals Private Limited is assessed as Moderate with a Trust Score of 72/100. Sancure Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2012, operating in the Trading sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Sancure Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
72/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
20/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 3 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SOUBHAGYA KUMAR MOHAPATRA 01234567 Director 01/04/2018 6 yrs Approved
AISWARYA DAS 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: AISWARYA DAS (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 55
Growth signals & trust indicators
Steady revenue growth: +1.42 over 2 year(s).
Latest year revenue grew 2.1x.
Asset base grew 24% - capacity expansion.
Operating for 13+ years.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Negative net worth.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment51/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view55/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 6 events
11 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
08 Dec 2017
Director ceased
NIRMAL KUMAR PUHAN
05 Dec 2012
Incorporated
Registered with Roc Cuttack
Director appointed
SOUBHAGYA KUMAR MOHAPATRA (Director)
Director appointed
AISWARYA DAS (Managing Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 2 financial year(s).
Net profit margin moved from 61% to 38%.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2017 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Therabimb Lifesciences Private Limited U24233MH2013PTC249347 Navi Mumbai, Maharashtra, India
Solanz Project Management Consultants Private Limited U74990MH2010PTC206883 Navi Mumbai, Maharashtra, India
Voler Advisory Private Limited U74999DL2016PTC301532 Delhi, Delhi, India
Nitin Associates Private Limited U51909DL1996PTC077894 Delhi, Delhi, India
Skilman Auto Technology Private Limited U29212PB1997PTC019863 Punjab, Punjab, India
Virtual Dealer Private Limited U51109WB2008PTC121878 Howrah, West Bengal, India
Stylish Mercantile Private Limited U51909WB2005PTC101198 Rajarhat, West Bengal, India
Swarn Comtrade Private Limited U51109WB2007PTC114007 Kolkata, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Sancure Pharmaceuticals Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Sancure Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 75/100, margin trends, ownership structure and peer set for Sancure Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 72/100, distress signals and MSME payment-delay disclosures - know whether Sancure Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Sancure Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Sancure Pharmaceuticals Private Limited an active company?

Sancure Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Sancure Pharmaceuticals Private Limited financially healthy?

Sancure Pharmaceuticals Private Limited has a Financial Health Score of 20/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Sancure Pharmaceuticals Private Limited?

Its overall Trust Score is 72/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Sancure Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Sancure Pharmaceuticals Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Sancure Pharmaceuticals Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Sancure Pharmaceuticals Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.